Processed and formatted by SEC Watch - Visit SECWatch.

com

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: February 13, 2009

PURE BIOSCIENCE
(Exact name of registrant as specified in its charter)

California 33-0530289

(State or other jurisdiction (I.R.S. Employer

of incorporation or organization) Identification No.)

1725 Gillespie Way, El Cajon, California 92020

(Address of principal executive offices)(Zip Code)

(619) 596 8600

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Processed and formatted by SEC Watch - Visit SECWatch.com

Item 5.02 Departure of Directors of Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory
Arrangements of Certain Officers.

On February 13, 2009, Murray Gross resigned as a director of Pure Bioscience. Mr. Gross was a member of the Audit and Compensation
Committees of Pure Bioscience. Mr. Gross resigned in order to address business concerns unrelated to Pure Bioscience requiring greater time
and attention. Mr. Gross’ resignation was not the result of any disagreement with respect to the company’s policies, practices or operations.
The Board of directors has expressed its gratitude and appreciation for the service to the Corporation by Mr. Gross.

The registrant has provided Mr. Gross with a copy of this current report prior to the filing thereof and informed him that he had the
opportunity to provide the registrant with correspondence stating whether he agrees or disagrees with the disclosure contained in this current
report which the registrant would also file such correspondence as an exhibit to this current report or an amendment thereto.

Item 9.01. Financial Statements and Exhibits

(d) The following exhibits are filed with this report:

Exhibit Description
Number

17.1 Resignation of Murray Gross dated February 13, 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.

PURE BIOSCIENCE

Dated: February 20, 2009

/s/ Michael L. Krall

Michael L. Krall, Chief Executive Officer
 Processed and formatted by SEC Watch - Visit SECWatch.com

EXHIBIT 17.1

MURRAY H. GROSS
4490 Live Oak Boulevard, Delray Beach, Florida 33445
Office: 214.488 6300, ext. 250; Fax: 972.459.4800
Residence: 561.496.1169; Fax: 561.496.5523

February 13, 2009

Mr. Michael L. Krall

President, CEO and Chairman of the Board
PURE BioScience
1725 Gillespie Way
El Cajon, California 92020

Dear Michael:

As you know, I am the CEO and Chairman of the Board of U. S. Home Systems, Inc. As a result of the recent departure of U. S. Home Systems’
president and chief operating officer, it has become necessary for me to resume the position of president and devote additional time to the
daily management and operations of USHS. With these additional responsibilities and time commitments, I will no longer be able to devote the
time that I believe is necessary to fulfill my duties and responsibilities as a director of PURE BioScience.

Therefore, it is with deep regret that I am hereby tendering my resignation as a director of PURE BioScience effective February 13, 2009.

I wish you and PURE BioScience continued success in the future.

Very truly yours,

/s/ Murray H. Gross

Murray H. Gross

MHG:dks